Protein Summary
Implicated in chromosome condensation and DNA damage induced cellular responses. May play a role in neurogenesis and regulation of the size of the cerebral cortex. This gene encodes a DNA damage response protein. The encoded protein may play a role in G2/M checkpoint arrest via maintenance of inhibitory phosphorylation of cyclin-dependent kinase 1. Mutations in this gene have been associated with primary autosomal recessive microcephaly 1 and premature chromosome condensation syndrome. Alternatively spliced transcript variants have been described. [provided by RefSeq, Feb 2010]
- ENST00000344683
- ENSP00000342924
- ENSG00000147316
- ENST00000519480
- ENSP00000430962
- ENST00000522905
- ENSP00000430768
- ENST00000643429
- ENSP00000496505
- ENSG00000285262
- ENST00000646478
- ENSP00000494584
- ENST00000647051
- ENSP00000493874
- MCT
- BRIT1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
virus perturbation | 0.99 | ||
histone modification site profile | 0.89 | ||
transcription factor perturbation | 0.88 | ||
transcription factor binding site profile | 0.87 | ||
trait | 0.75 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 141.29 (req: < 5)
Gene RIFs: 83 (req: <= 3)
Antibodies: 325 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 141.29 (req: >= 5)
Gene RIFs: 83 (req: > 3)
Antibodies: 325 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 12
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0